EP Vantage
EP Vantage
Stop FollowingEP Vantage
View as an RSS Feed
View EP Vantage's Articles BY TICKER:
ABII,
ABT,
AFFY,
ALIM,
ALIOF.PK,
ALNY,
ALTH,
ALXN,
AMGN,
ARIA,
ARQL,
ASTM,
AZN,
BAX,
BCRX,
BMTI,
BMY,
BSNRF.PK,
BSX,
CADX,
CBST,
CELG,
CEPH,
CHTP,
CORT,
COV,
CYPB,
CYTK,
DDSS,
DEPO,
DMYDF.PK,
DNDN,
ECYT,
ESALY.PK,
EW,
FOLD,
FRX,
GE,
GILD,
GSK,
GTXI,
HALO,
HEB,
IMGN,
INHX,
ISPH,
ISTA,
ITMN,
JAZZ,
JNJ,
KG,
LLY,
LMNX,
MDCO,
MDT,
MDVN,
MEDX,
MKGAF.PK,
MNKD,
MYGN,
NAVB,
NEUSF.PK,
NVS,
NYMX,
OMER,
ONXX,
OPOSF.PK,
PARD.PK,
PCYC,
PFE,
PPHM,
RHHBY.OB,
RIGL,
SCR,
SNN,
SNY,
STJ,
SVNT,
SXMDF.PK,
TEVA,
THRX,
TMO,
UCBJY.PK,
UTHR,
VPHM,
VRX,
VVUS,
WILLF.PK,
WMGI,
YMI
- Healthpoint Buy To Double Smith & Nephew's U.S. Wound Operations
- Baxter Getting Its Blood Pumping Over Gambro
- BioMimetic Buy Could Augment Wright's Orthopaedic Offering
- Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Uses
- Boston Scientific Gatecrashes Renal Denervation Market With Vessix Buy
- AHA - 2 Hits And Several Misses With Novartis' Serelaxin
- St. Jude's Amplatzer Can't Cure A Broken Heart
- Edwards Tries To Put Poor Sales Behind It With BMEYE Buy
- Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB Shares
- Medivation Gets Surprise Early Approval For Prostate Cancer Pill
- Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
- Sanofi And Regeneron Maintain Lead In Race For PCSK9 Success
- Investor Demands On Astra's Cash Shows Industry Must Improve R&D Prowess
- Austerity Pressures AMD Drug Pricing As Avastin Attracts
- AstraZeneca Hopes To Take Off Heat With Gout Acquisition
- Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations
- Endocyte Gets Big Deal But More Validation Needed
- Intermune's Long Slog With Esbriet Shows No Sign Of Quickening
- AstraZeneca Spreads The Load With Amgen Development Deal
- Endocyte Stages Comeback On Filing News
- Omeros Eyeing Deals As Ophthalmology Drug Succeeds
- Roche Scores Important Win With Actemra
- Vivus: FDA Panel Clears Qnexa's Path To Market
- Corcept Scores A First With Cushing's Treatment Approval In The U.S.
- AstraZeneca's Shrinking Act Could Increase Its Appeal
- For Theravance Investors, GlaxoSmithKline Won't Be The Answer
- Biotech Investors Buoyed By Signs Of Speedier Drug Launches
- Alexion Continues To Please Orphan Fans
- Valeant's Hostile Bid For ISTA
- Covidien, Abbott Setting A Spin-Out Trend
- YM's Positive Results Have Incyte Investors Worried
- Onyx's Myeloma Drug Shifts To The Slow Lane